Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially fatal condition which impedes blood flow by causing blood clots (thrombosis) (Wendelboe et al., 2021). In a VTE, a DVT is a clot that occurs only in the veins; DVT is commonly found in the legs and pelvis (proximally) but can also occur in the upper body (distally) (Henke et al., 2020). If the DVT travels from its original location through the circulatory system to the lungs, restricting, or blocking, blood supply, this is known as a PE (Henke et al., 2020; Patel et al., 2020). The clinical presentation of both DVT, and PE, is non-specific, at times asymptomatic, and can often result in sudden death. The high recurrence risk, and high mortality rate complicates the diagnostic and treatment process for VTE (Ageno et al., 2021).
The analyst epidemiologists utilized comprehensive, country-specific VTE data from nationally representative, market-specific sources to forecast the diagnosed incident cases and attack rates of VTE in the 7MM. Robust nationally representative sources were used to forecast the medically ill population at risk of VTE, and the number of knee and hip replacements across the 7MM. Moreover, The analyst epidemiologists provided detailed age- and sex-segmentations, with additional segmentation by anatomical region, provoking risk factor, and comorbidities (including cancer and CKD). Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes throughout the forecast period.
The analyst epidemiologists forecast that the diagnosed incident cases of VTE will increase from 1,500,492 cases in 2024, to 1,710,302 cases in 2034, at an annual growth rate (AGR) of 1.41%. The number of VTE attacks is forecast to grow from 1,628,710 in 2024 to 1,859,433 in 2034 in the 7MM, at an AGR of 1.42%. The analyst epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 7MM from 14,454,096 in 2024 to 15,821, 202 in 2034.
The analyst epidemiologists utilized comprehensive, country-specific VTE data from nationally representative, market-specific sources to forecast the diagnosed incident cases and attack rates of VTE in the 7MM. Robust nationally representative sources were used to forecast the medically ill population at risk of VTE, and the number of knee and hip replacements across the 7MM. Moreover, The analyst epidemiologists provided detailed age- and sex-segmentations, with additional segmentation by anatomical region, provoking risk factor, and comorbidities (including cancer and CKD). Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes throughout the forecast period.
The analyst epidemiologists forecast that the diagnosed incident cases of VTE will increase from 1,500,492 cases in 2024, to 1,710,302 cases in 2034, at an annual growth rate (AGR) of 1.41%. The number of VTE attacks is forecast to grow from 1,628,710 in 2024 to 1,859,433 in 2034 in the 7MM, at an AGR of 1.42%. The analyst epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 7MM from 14,454,096 in 2024 to 15,821, 202 in 2034.
Report Scope
- VTE model and report provides an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of PE, DVT, and VTE, each segmented by age and sex. Diagnosed incident cases of DVT is segmented by anatomical region and diagnosed incident cases of VTE by provoking risk factor. VTE recurrence at one and 10 years, VTE cases with cancer and chronic kidney disease as comorbidity, and the number of VTE attacks is also included.
- This report also includes a 10-year epidemiological forecast of medically ill patients discharged from hospital that are at risk for VTE, the number of primary total knee replacements and revisions, and the number of hip replacements.
Reasons to Buy
- Venous Thromboembolism Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global VTE markets.
- Quantify patient populations in the global VTE markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered.
- Understand magnitude of the VTE population by age, sex, anatomical region, comorbidity, and provoking risk factor.
Table of Contents
1 Venous Thromboembolism (VTE): Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
